The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions.
The close relationship between the biological behaviour of malignant cells and the local microenvironment where they reside is a feature of diverse neoplasias. Multiple myeloma (MM) is considered a main disease model for the study of such interactions and the mechanisms that can lead to bone-related clinical complications, as well as the role of these interactions in attenuating the activity of conventional anti-MM therapeutics, such as dexamethasone and cytotoxic chemotherapeutics. This review focuses on recent progress in the study of interactions of MM cells with their local microenvironment. Major emphasis is placed on how bone marrow stromal cells (BMSCs) and other normal constituents of the bone marrow milieu promote, through cell adhesion- and cytokine-mediated mechanisms, the ability of MM cells to resist conventional anti-MM therapies. The review also addresses ongoing research into these mechanisms, which has already provided several new molecular targets and corresponding therapeutic strategies, such as the proteasome inhibitor bortezomib and thalidomide derivatives (e.g. lenalidomide), for the management of myeloma.
Mitsiades
Constantine S
CS
Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street Boston, MA 02115, USA. constantinte_mitsiades@dfci.harvard.edu
Mitsiades
Nicholas S
NS
Munshi
Nikhil C
NC
Richardson
Paul G
PG
Anderson
Kenneth C
KC
D001847:Bone Diseases / Q000209:etiology* / Q000628:therapy; D002450:Cell Communication; D006133:Growth Substances / Q000502:physiology*; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications*; D017978:Receptors, Growth Factor / Q000502:physiology*; D017154:Stromal Cells / Q000502:physiology*
D006133:Growth Substances; D017978:Receptors, Growth Factor